头孢吡肟
哌拉西林/他唑巴坦
哌拉西林
头孢菌素
他唑巴坦
肺炎
医学
内科学
碳青霉烯
临床终点
危险系数
抗生素
置信区间
微生物学
随机对照试验
亚胺培南
生物
抗生素耐药性
遗传学
细菌
铜绿假单胞菌
作者
Alexis Maillard,Tristan Delory,Juliette Bernier,Antoine Villa,Khalil Chaïbi,L. Escaut,Adrien Contejean,Béatrice Berçot,Jérome Robert,Fatma El Alaoui,Jacques Tankovic,Hélène Poupet,Gaëlle Cuzon,Matthieu Lafaurie,Laure Surgers,Adrien Joseph,Olivier Paccoud,Jean‐Michel Molina,Alexandre Bleibtreu
标识
DOI:10.1016/j.ijantimicag.2023.106809
摘要
The optimal treatment regimen for infections caused by wild-type AmpC β-lactamase-producing Enterobacterales remains controversial. This study compared the outcomes of bloodstream infections (BSI) and pneumonia according to the type of definitive antibiotic therapy: third-generation cephalosporin (3GC), piperacillin ± tazobactam, cefepime or carbapenem. All cases of BSI and pneumonia caused by wild-type AmpC β-lactamase-producing Enterobacterales over 2 years in eight university hospitals were reviewed. Patients who received definitive therapy consisting of either a 3GC (3GC group), piperacillin ± tazobactam (piperacillin group), or cefepime or a carbapenem (reference group) were included in this study. The primary endpoint was 30-day all-cause mortality. The secondary endpoint was treatment failure due to infection by emerging AmpC-overproducing strains. Propensity-score-based models were used to balance confounding factors between groups. In total, 575 patients were included in this study: 302 (52%) with pneumonia and 273 (48%) with BSI. Half (n=271, 47%) received cefepime or a carbapenem as definitive therapy, 120 (21%) received a 3GC, and 184 (32%) received piperacillin ± tazobactam. Compared with the reference group, 30-day mortality was similar in the 3GC [adjusted hazard ratio (aHR) 0.86, 95% confidence interval (CI) 0.57–1.31)] and piperacillin (aHR 1.20, 95% CI 0.86–1.66) groups. The likelihood of treatment failure was higher in the 3GC (aHR 6.81, 95% CI 3.76–12.4) and piperacillin (aHR 3.13, 95% CI 1.69–5.80) groups. The results were similar when stratifying the analysis on pneumonia or BSI. Treatment of included BSI or pneumonia caused by wild-type AmpC β-lactamase-producing Enterobacterales with 3GC or piperacillin ± tazobactam was not associated with higher mortality, but was associated with increased risk of AmpC overproduction leading to treatment failure compared with cefepime or a carbapenem.
科研通智能强力驱动
Strongly Powered by AbleSci AI